SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

04 Feb 2022 Evaluate
A fair growth of 22.61% in the revenue at Rs. 21808.40 millions was reported in the December 2021 quarter as compared to Rs. 17787.50 millions during year-ago period.The Company has registered profit of Rs. 4370.90  millions for the quarter ended December 2021, a growth of 9.01%  over Rs. 4009.80 millions millions achieved in the corresponding quarter of last year.Operating profit surged to 5355.00 millions from the corresponding previous quarter of 5156.30 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 21808.40 17787.50 22.61 68235.00 53022.10 28.69 72196.80 66770.80 8.13
Other Income 632.40 724.60 -12.72 1456.60 1412.40 3.13 1900.10 959.80 97.97
PBIDT 5355.00 5156.30 3.85 17563.30 16737.60 4.93 21389.40 15636.30 36.79
Interest 72.60 87.70 -17.22 248.20 355.70 -30.22 429.30 387.10 10.90
PBDT 5282.40 5068.60 4.22 17315.10 16381.90 5.70 20832.30 15249.20 36.61
Depreciation 584.30 500.80 16.67 1639.70 1495.50 9.64 1989.30 1868.40 6.47
PBT 4698.10 4567.80 2.85 15675.40 14886.40 5.30 18843.00 13380.80 40.82
TAX 327.20 558.00 -41.36 1031.70 1663.00 -37.96 1992.20 736.60 170.46
Deferred Tax -481.10 -242.70 98.23 -1682.40 -945.90 77.86 -1326.10 -1732.90 -23.48
PAT 4370.90 4009.80 9.01 14643.70 13223.40 10.74 16850.80 12644.20 33.27
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 24.55 28.99 -15.29 25.74 31.57 -18.46 29.63 23.42 26.51

Alkem Laboratories Share Price

5646.60 62.90 (1.13%)
20-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×